Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the grand opening of its new Repligen Training & Innovation Center (“RTIC”) ...

A number of stocks jumped in the afternoon session after the reopening of the Strait of Hormuz signaled a cooling of global ...

NEW YORK (Reuters) -Repligen, a provider of drug manufacturing equipment, has approached Maravai LifeSciences Holdings, a vaccine capping reagent vendor that has a market value of about $2.5 billion, ...

Fintel reports that on April 17, 2026, Roth Capital initiated coverage of Repligen (NasdaqGS:RGEN) with a Buy recommendation.

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) in Q4 CY2024, but sales were flat year on year at $167.5 million. The company’s outlook for the full year was close to analysts’ ...

WALTHAM, Mass., June 22, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into ...

The United States market has shown robust growth, rising 4.2% over the last week and 29% over the past year, with earnings projected to increase by 16% annually. In such a thriving environment, ...

Avitide, a company that spun out of an Ivy League lab with a way to quickly and efficiently purify biologic drugs, is being acquired for $150 million by global bioprocessing vendor Repligen, which ...

Less than a decade ago, Repligen (RGEN +0.02%) was toiling away in clinical trials in an attempt to bring experimental drugs to market. Today, the company's former drug pipeline is a distant memory.

Smaller players in the life sciences industry are being scooped up. Repligen has masterfully done this to grow and stay competitive. The strategy has left some baggage on its financial statements.

The stock price of Repligen (NASDAQ: RGEN), a U.S.-based life sciences company involved in production of materials used in the manufacture of biological drugs, has seen a 12% drop over the last twenty ...